Mantle Cell Lymphoma;ibrutinib;venetoclax

ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax

[ad_1] ABSTRACT: LBA-2 Newswise — SAN DIEGO ― The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival…